Objectives: Antimicrobial resistance is a major threat to public health. New drugs such as Ceftazidime/avibactam have been developed for the treatment of Multi-Drug resistant (MDR) pathogens. Susceptibility can be variable and inappropriate use can add a financial strain on the National Health Service (NHS). There is a pressing need to ensure these new and invaluable antimicrobials are preserved and used effectively.
Methods: We undertook a retrospective observational study to assess the use of Ceftazidime/avibactam and evaluated prescribing against applied standards.
Results: Between August 2017 and January 2019, 28 patients received 31 courses of Ceftazidime/avibactam. Prescribing according to the approved indications was observed for 68% of prescriptions (p < 0.0001). Duration of therapy was often prolonged but improved with Antimicrobial stewardship interventions. We observed 56% susceptibility (15/27 isolates) of MDR organisms (. We also report first experience to treat pulmonary disease caused by Non-tuberculous mycobacteria (NTM). Ceftazidime/avibactam was well tolerated, with no evidence of development of resistance at 6-months follow-up.
Conclusions: Our study showed that Antimicrobial stewardship interventions led to a more appropriate use of Ceftazidime/avibactam (as measured by duration of therapy), preserving it as a treatment option for MDR infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14787210.2020.1810568 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producing during antimicrobial chemotherapy.
Antimicrob Agents Chemother
December 2024
Department of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
The global rise of carbapenem-resistant , including strains producing carbapenemase (KPC) types, poses a significant public health challenge due to their resistance to critical antibiotics. Treatment options for infections caused by KPC-producing (KPC-KP) are increasingly limited, particularly as these strains develop resistance to last-line antibiotics such as ceftazidime/avibactam and colistin. This study investigates the evolution of antibiotic resistance and persistence in a series of clonally related ST11 KPC-KP strains isolated from a single patient undergoing extended antimicrobial treatment.
View Article and Find Full Text PDFEfficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant infections after initial treatment with polymyxin.
Microbiol Spectr
November 2024
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Although polymyxins are a suboptimal option for difficult-to-treat resistant infections, they are still preferred as the first-line treatment, especially in low- and middle-income countries. This study assesses the efficacy of ceftazidime-avibactam (CAZ-AVI) following polymyxin B failure in patients with carbapenem-resistant (CRKP) infections. We retrospectively reviewed cases of infections caused by CRKP in adults who received CAZ-AVI as salvage therapy.
View Article and Find Full Text PDFCeftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
Health Technol Assess
October 2024
Centre for Health Economics, University of York, York, UK.
Background: To limit the use of antimicrobials without disincentivising the development of novel antimicrobials, there is interest in establishing innovative models that fund antimicrobials based on an evaluation of their value as opposed to the volumes used. The aim of this project was to evaluate the population-level health benefit of ceftazidime-avibactam in the NHS in England, for the treatment of severe aerobic Gram-negative bacterial infections when used within its licensed indications. The results were used to inform National Institute for Health and Care Excellence guidance in support of commercial discussions regarding contract value between the manufacturer and NHS England.
View Article and Find Full Text PDFEmerging Colistin Resistance: Experience from an Intensive Care Unit of a Tertiary Care Center in India.
J Assoc Physicians India
October 2024
Professor, Department of Critical Care Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Article Synopsis
- There is a growing global concern about antimicrobial resistance, particularly with the rise of carbapenem and colistin resistance, especially in ICU settings of Southeast Asia like India.
- The study focused on analyzing the clinical outcomes of ICU patients who had polymyxin B/E (colistin) resistant infections by comparing them to those with sensitive infections, collecting various clinical and demographic data.
- Conducted in a northern India ICU, the research included 28 patients with resistant infections and 55 controls, assessing factors such as ICU stay length and treatment outcomes using established statistical methods.
Clinical experience with ceftazidime/avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children.
Eur J Clin Microbiol Infect Dis
December 2024
Faculty of Medicine, Cukurova University, Adana, Turkey.
Purpose: Klebsiella pneumoniae is a significant cause of healthcare-associated infections, resulting in high morbidity and mortality rates due to limited treatment options. In this study, we aimed to evaluate the treatment outcomes and the safety of Ceftazidime-avibactam in infections caused by extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in pediatric patients.
Methods: This study included pediatric patients who received ceftazidime-avibactam treatment due to extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae infections, monitored in the pediatric intensive care, neonatal intensive care, and pediatric wards of Cukurova University Faculty of Medicine between 2022 and 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!